Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

July 24, 2026

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain penetration designed for the treatment of Parkinson’s disease.

BioWorld Science Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...

Other news to note for July 22, 2026

BioWorld

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...